Literature DB >> 10507180

[Historical review of smallpox, the eradication of smallpox and the attenuated smallpox MVA vaccine].

A Mayr1.   

Abstract

After the WHO had declared smallpox to be eradicated in 1980, smallpox vaccination ceased to be carried out in humans all over the world. The cutaneous inoculations carried out with live vaccines based on the vaccinia virus from 1798 onwards protected both the global population and, indirectly, the animals living with humans against orthopox infections in general. A large percentage of humans and animals no longer enjoy this protection. Idiopathic orthopox in animals (reservoir possibly rats and mice) are thus experiencing a renaissance, posing a threat to humans and animals. The paper provides an historical retrospective of smallpox epidemics in humankind, their course of development and methods employed to combat this disease, commencing long before the birth of Christ with primitive attempts in China and India and from the end of the 18th century with increasingly enhanced methods, most recently with worldwide smallpox vaccination programmes using live vaccinia vaccines. Smallpox vaccination was always accompanied by a variety of complications, especially postvaccinal encephalitis. The MVA strain was developed to reduce or prevent such adverse effects. MVA has meanwhile proved its worth both as a parenteral vaccine against orthopox infections in humans and animals and as a vector for insertion of foreign genes. The history of smallpox, the fight against this disease and the development of MVA are documented with the help of figures and tables.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10507180

Source DB:  PubMed          Journal:  Berl Munch Tierarztl Wochenschr        ISSN: 0005-9366            Impact factor:   0.328


  7 in total

1.  Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1.

Authors:  Zhongde Wang; Corinna La Rosa; Zhongqi Li; Heang Ly; Aparna Krishnan; Joy Martinez; William J Britt; Don J Diamond
Journal:  Vaccine       Date:  2006-10-06       Impact factor: 3.641

2.  Current Status for High Titre Poxvirus Stock Preparation in CEF Under Serum-Free Medium Conditions: Implication for Vaccine Development.

Authors:  Philippe-Alexandre Gilbert; Lacrimioara Comanita; John Barrett; Andrew Peters; Marta Szabat; Grant McFadden; Gregory A Dekaban
Journal:  Cytotechnology       Date:  2005-06       Impact factor: 2.058

3.  MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults.

Authors:  Corinna La Rosa; Jeff Longmate; Joy Martinez; Qiao Zhou; Teodora I Kaltcheva; Weimin Tsai; Jennifer Drake; Mary Carroll; Felix Wussow; Flavia Chiuppesi; Nicola Hardwick; Sanjeet Dadwal; Ibrahim Aldoss; Ryotaro Nakamura; John A Zaia; Don J Diamond
Journal:  Blood       Date:  2016-10-19       Impact factor: 22.113

4.  Expression of CCL20 and granulocyte-macrophage colony-stimulating factor, but not Flt3-L, from modified vaccinia virus ankara enhances antiviral cellular and humoral immune responses.

Authors:  R Chavan; K A Marfatia; I C An; D A Garber; M B Feinberg
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

Review 5.  Smallpox vaccines for biodefense.

Authors:  Richard B Kennedy; Inna Ovsyannikova; Gregory A Poland
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

Review 6.  Application of radiation technology in vaccines development.

Authors:  Ho Seong Seo
Journal:  Clin Exp Vaccine Res       Date:  2015-07-29

Review 7.  Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine.

Authors:  Xiuli Wang; Don J Diamond; Stephen J Forman; Ryotaro Nakamura
Journal:  Int J Hematol       Date:  2021-09-24       Impact factor: 2.490

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.